Abstract
Chronic inflammation increases the risk of developing cancer. For example, patients with severe and prolonged inflammatory bowel disease, particularly ulcerative colitis, have a significantly higher risk of developing colorectal cancer. Serine proteases coordinating the coagulation cascade and immune cell proteases play important roles in regulating the inflammatory response through their actions on protease-activated receptors (PAR). PARs and their activating proteases have also been implicated in many cancers, including CRC. Importantly, the actions of proteases could be important for mediating the transition from chronic inflammation to cancer. PAR activation has been shown to have pro-tumourigenic effects including the production of matrix metalloproteinases that can promote tumour cell growth and metastasis, and transactivation of the epidermal growth factor receptor, which is a main target for cancer treatment. Additionally, PAR activation can also result in increased expression of cyclooxygenase (COX)-2, an important enzyme mediating inflammation, resolution, and cancer progression. In this review, we will highlight our current knowledge about the effects of proteases and their receptors on intestinal inflammation and cancer, and explore the potential role of PAR-induced COX-2 on colitis-associated cancer.
Keywords: colitis-associated cancer, colorectal cancer, cyclooxygenase-2, inflammatory bowel disease, protease-activated receptors, serine proteases.
Current Pharmaceutical Design
Title:Proteases and their Receptors as Mediators of Inflammation-Associated Colon Cancer
Volume: 21 Issue: 21
Author(s): Elizabeth H. Trusevych and Wallace K. MacNaughton
Affiliation:
Keywords: colitis-associated cancer, colorectal cancer, cyclooxygenase-2, inflammatory bowel disease, protease-activated receptors, serine proteases.
Abstract: Chronic inflammation increases the risk of developing cancer. For example, patients with severe and prolonged inflammatory bowel disease, particularly ulcerative colitis, have a significantly higher risk of developing colorectal cancer. Serine proteases coordinating the coagulation cascade and immune cell proteases play important roles in regulating the inflammatory response through their actions on protease-activated receptors (PAR). PARs and their activating proteases have also been implicated in many cancers, including CRC. Importantly, the actions of proteases could be important for mediating the transition from chronic inflammation to cancer. PAR activation has been shown to have pro-tumourigenic effects including the production of matrix metalloproteinases that can promote tumour cell growth and metastasis, and transactivation of the epidermal growth factor receptor, which is a main target for cancer treatment. Additionally, PAR activation can also result in increased expression of cyclooxygenase (COX)-2, an important enzyme mediating inflammation, resolution, and cancer progression. In this review, we will highlight our current knowledge about the effects of proteases and their receptors on intestinal inflammation and cancer, and explore the potential role of PAR-induced COX-2 on colitis-associated cancer.
Export Options
About this article
Cite this article as:
Trusevych H. Elizabeth and MacNaughton K. Wallace, Proteases and their Receptors as Mediators of Inflammation-Associated Colon Cancer, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150514104800
DOI https://dx.doi.org/10.2174/1381612821666150514104800 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Development of Method for Three-Point Data Estimation and SVR-QSAR Model to Screen Anti Cancer Leads
Combinatorial Chemistry & High Throughput Screening Preface [Hot topic: Tumour-Selective Drug Activation (Executive Editor : L.H. Patterson)]
Current Pharmaceutical Design Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Histone Variants and Composition in the Developing Brain: Should MeCP2 Care?
Current Topics in Medicinal Chemistry Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Anti-Cancer Effect of Melatonin via Downregulation of Delta-like Ligand 4 in Estrogen-Responsive Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature.
Reviews on Recent Clinical Trials The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Curcumin, an Active Constiuent of the Ancient Medicinal Herb Curcuma longa L.: Some Uses and the Establishment and Biological Basis of Medical Efficacy
CNS & Neurological Disorders - Drug Targets Targeted Therapy of Breast Cancer
Current Pharmaceutical Design Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology COMMENTARY: Pre-emptive Nutrition: Refining the Targets of Drugs Targeted to Colorectal Cancer
Current Cancer Drug Targets Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity
Current Medicinal Chemistry